Crinetics Pharmaceuticals (CRNX) Change in Acquisitions & Divestments (2019 - 2026)

Crinetics Pharmaceuticals' Change in Acquisitions & Divestments history runs 8 years deep, the most recent figure standing at $302.9 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 1.17% year-over-year to $302.9 million in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 51.17% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 105.64% from the prior year.
• Change in Acquisitions & Divestments advanced to $302.9 million in Q1 2026 per CRNX's latest filing, from $271.2 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $382.4 million in Q3 2025 and bottomed at $11.7 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $101.4 million (2024), against an average of $150.4 million.
• Biggest YoY gain for Change in Acquisitions & Divestments was 28870.49% in 2022; the steepest drop was 66.66% in 2022.
• Year by year, Change in Acquisitions & Divestments stood at $70.7 million in 2022, then advanced by 22.62% to $86.7 million in 2023, then soared by 112.24% to $184.0 million in 2024, then soared by 47.42% to $271.2 million in 2025, then advanced by 11.68% to $302.9 million in 2026.
• Per Business Quant, the three latest CRNX Change in Acquisitions & Divestments figures stand at $302.9 million (Q1 2026), $271.2 million (Q4 2025), and $382.4 million (Q3 2025).